Compare Vanguard S&P 500 Growth Index Fund ETF (VOOG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard S&P 500 Growth Index Fund ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Vanguard S&P 500 Growth Index Fund ETF trades at $87.27 (market cap $27.10B), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.7× Vanguard S&P 500 Growth Index Fund ETF's market cap, and Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard S&P 500 Growth Index Fund ETF for 54 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| VOOG | VRTX | |
|---|---|---|
Market Cap | $27.10B | $127.55B |
Volume | 1,178,312 | 1,487,944 |
Sector | Broad Market / Factor | Health |
52-Week High | $87.81 | $557.96 |
52-Week Low | $65.32 | $407.37 |
Typical Hold Time | 54 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VOOG trades at $87.69, down slightly by 0.14% on the day, with technical indicators showing mixed signals—bullish moving averages but bearish oscillators including an overbought RSI. The ETF, tracking the S&P 500 Growth Index, has delivered strong long-term returns, with recent news highlighting institutional buying and outperformance versus peers. Key support sits at $87, resistance at $88.
Outlook remains positive for long-term growth investors given VOOG's low expense ratio and historical outperformance, though near-term risks include tech sector concentration and market volatility. The ETF's focus on large-cap growth stocks positions it well for sustained appreciation, but investors should be cautious of valuation extremes in growth segments.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
